Indications & Uses
Paroxib is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Dosage Adult: The recommended dose is 40 mg administered intravenously (IV) or intramuscularly (IM), followed every 6 to 12 hours by 20 mg or 40 mg as required, not to exceed 80 mg/day. As the cardiovascular risk of COX-2 specific inhibitors may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. There is limited clinical experience with Parecoxib treatment beyond three days.Elderly: No dose adjustment is generally necessary in elderly patients (≥65 years). However, for elderly patients weighing less than 50 kg, treatment should be initiated with half the usual recommended dose of Parecoxib and reduce the maximum daily dose to 40 mg.Children: The safety and efficacy of parecoxib in children under 18 years old have not been established. No data are available. Therefore, parecoxib is not recommended in these patients.
Side Effects
Commonside effects are- Change in your blood pressure (up or down) You may get back pain Ankles, legs and feet may swell (fluid retention) You may feel numb- your skin may lose sensitivity to pain and touch You may get vomiting, stomach ache, indigestion, constipation, bloating and wind Tests may show abnormal kidney function You may feel agitated or find it hard to sleep Dizziness There is a risk of anaemia- changes in red blood cells after an operation that may cause fatigue and breathlessness You may get a sore throat or difficulty breathing (shortness of breath) Your skin may be itchy You may pass less urine than usual. Dry socket (inflammation and pain after a tooth extraction) Increased sweating Low levels of potassium in blood test results.
Cautions & Contraindications
Warnings & Precautions
Coxpar has been studied in dental, orthopaedic, gynaecologic (principally hysterectomy) and coronary artery bypass graft surgery. There is limited experience in other types of surgery, for example gastrointestinal or urological surgery. Modes of administration other than IV or IM (e.g. intra-articular, intrathecal) have not been studied and should not be used. Because of the possibility for increaed adverse reactions at higher doses of Coxpar, other COX-2 inhibitors and NSAIDs, patients treated with Coxpar should be reviewed following dose increase and, in the absence of an increase in efficacy, other therapeutic options should be considered. There is limited clinical experience with Coxpar treatment beyond three days. If, during treatment, patients deteriorate in any of the organ system functions described below, appropriate measures should be taken and discontinuation of Coxpar therapy should be considered.
Contraindications
Hypersensitivity to the active substance or to any of the excipients.